i
Change in testing for blood glucose during the COVID-19 pandemic, United States 2019–2021
-
11 2023
-
-
Source: Diabetes Res Clin Pract. 205:110985
Details:
-
Alternative Title:Diabetes Res Clin Pract
-
Personal Author:
-
Description:Aim:
This study assessed changes in testing for blood glucose in the United States (US) from 2019 to 2021.
Methods:
We conducted a serial cross-sectional analysis of the 2019–2021 National Health Interview Survey by including adults aged ≥ 18 years without reported diagnosed diabetes. We estimated the prevalence of testing for blood glucose within 12 months and the difference in the testing prevalence between 2019 and 2021.
Results:
The study sample included 82,594 respondents without diabetes in 2019––2021, with a mean age between 46.4 and 46.8 years. Overall, the prevalence of testing for blood glucose decreased significantly from 64.2 % (95 % confidence interval [CI] 63.3 %, 65.1 %) in 2019 to 60.0 % (95 % CI 59.1 %, 60.9 %) in 2021. Among adults who met the United States Preventive Services Task Force’s 2015 screening recommendation, the prevalence decreased from 73.4 % (95 % CI 72.2 %, 74.6 %) to 69.5 % (95 % CI 68.3 %, 70.6 %). Although decreases in testing were observed in most groups, the extent of the decline differed by subgroups.
Conclusions:
Testing for blood glucose decreased in the US during the COVID-19 pandemic. This may have delayed diagnosis and treatment of prediabetes and diabetes, underscoring the importance of continued access to diabetes screening during pandemics.
-
Subjects:
-
Keywords:
-
Source:
-
Pubmed ID:38968092
-
Pubmed Central ID:PMC11226753
-
Document Type:
-
Funding:
-
Collection(s):
-
Main Document Checksum:
-
Download URL:
-
File Type: